FDA Accused Of Cutting Obesity Drug's Exclusivity Short
Eisai Co. Ltd. on Friday accused the U.S. Food and Drug Administration of unfairly shortening its five-year exclusivity period for obesity drug Belviq by starting the clock when approval came through,...To view the full article, register now.
Already a subscriber? Click here to view full article